Business Wire

INKA Entworks Announces $8.2 Million Investment to Drive Global Expansion and AI-Driven Product Innovation

21.1.2025 16:00:00 EET | Business Wire | Press release

Share

INKA Entworks, a global leader in video content security and mobile app security solutions, has secured $8.2 million in a funding round led by SV Investment, with co-investments from DSC Investment, Stonebridge Ventures, Inopolis Partners, and IBK Industrial Bank. This investment reinforces INKA Entworks' position as a market leader and sets the stage for significant growth and innovation in 2025 and beyond.

The funding will enable INKA Entworks to expand its portfolio of cutting-edge video content security and robust mobile app security Saas solutions. The company aims to deliver advanced revenue-securing technologies to key markets, including media, sports, banking, fintech, and retail, while also driving product enhancements leveraging AI capabilities. Additionally, the funding will accelerate INKA Entworks' expansion into the U.S. and European markets and bolster its recruitment efforts to attract top talent.

Lee Sung-min, Team Leader of SV Investment’s VC Division, commented, “It is remarkable that a domestic software company has achieved phenomenal growth with 60% of revenue coming from overseas. This investment will support INKA Entworks in securing major North American and European clients and solidifying its leadership in the video content and app security markets with AI-driven solutions.”

INKA Entworks has achieved an impressive compound annual growth rate (CAGR) of 43% in overseas sales over the past three years, underscoring its ability to scale effectively. The company’s innovative SaaS solutions PallyCon and AppSealing have been instrumental in preventing hacking and illegal duplication, earning the trust of content operators and mobile app developers worldwide. Its clientele includes prominent names such as DAZN, Schneider Electric, PCCW, VIU, Vidio, LGU+, Bajajfinsev, and Prasar Bharti showcasing its broad industry reach.

“As the first domestic company to provide mobile app and content security technologies in a SaaS format, we have contributed to the growth of the security industry,” said James Sungmin Ahn, CEO of INKA Entworks. “This investment will solidify our position in South Korea and propel our efforts to succeed globally.”

The company’s immediate focus includes enhancing product innovation, expanding its global reach, and strengthening its leadership to set new benchmarks in digital security, paving the way for a secure digital future.

About INKA Entworks

INKA Entworks is a global leader in content security and mobile app security solutions, providing innovative technologies to protect digital assets across industries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250120715815/en/

Contacts

Media Contact:
Rupesh Shinde
obiz@inka.co.kr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye